PDSB - PDS Biotech triple combo cancer therapy shows promise in ongoing mid-stage study

PDS Biotechnology (NASDAQ:PDSB) reported data from an ongoing phase 2 trial of PDS0101 in combination with M9241 and bintrafusp alfa in certain cancers. The triple combination is being evaluated in patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar cancers who have failed prior therapy. These patients included people who had not received (naive) Immune checkpoint inhibitors (CPI) and also those who were resistant (refractory) to CPI drugs. The company said PDS0101 was administered as two separate 0.5 ml subcutaneous injections every 4 weeks; bintrafusp alfa at 1,200 mg by IV infusion every 2 weeks; and M9241 at an initial high dose of 16.8 mcg/kg by subcutaneous injection every 4 weeks or at a low dose of 8 mcg/kg by subcutaneous injection every 2 weeks. Data from 30 patients is being presented by the company at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The company said

For further details see:

PDS Biotech triple combo cancer therapy shows promise in ongoing mid-stage study